KYMR kymeratx.com: Net Assets per Single Share

Official company branding of Kymera (KYMR)

This daily price chart for Kymera Therapeutics (KYMR) shows figures at 18.27. Kymera Therapeutics leads in creating innovative platforms for the degradation of oncogenic proteins, which shields the company from price competition. The business relies on PROTAC technology to eliminate pathogenic proteins in tumor therapy. The diversity of agents under development to combat immune dysfunction and cancer minimizes scientific risks while expanding target market reach.

KYMR Kymera Therapeutics Inc Net Asset Value per Share (07/04/2022 - 10/29/2026)

KYMR (kymeratx.com): analytical breakdowns and indicator data

- current quotes and average value forecast:
Price Chart Kymera Therapeutics Inc|KYMR - Consensus Target
- company stock capitalization data:
Market Value Kymera|KYMR - Value Adjusted for Debt and Cash
- shareholders' equity book value data:
Net Assets per Single Share Kymera Therapeutics|KYMR - Total Stockholders' Equity|Market Value to Book Value Ratio kymeratx.com|KYMR - Total Business Assets
- debt obligations and liquidity statistics:
Total Debt to Capital Kymera Therapeutics|KYMR - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Kymera|KYMR - Company Cumulative Debt|Debt to Book Capitalization Ratio Kymera|KYMR - Company Long-Term Debt|Company Short-Term Debt Kymera Therapeutics|Quick Ratio kymeratx.com
- earnings and multiples data:
KYMR - Annual Net Income
Basic company analysis:KYMR - Kymera Therapeutics Inc
Manufactured products of Kymera

Investors are seeking a fundamental balance between asset quality and the market price of Kymera Therapeutics (KYMR). This indicator determines the equity per share after deducting all liabilities. For Kymera Therapeutics (KYMR), this metric reflects the value of specialized infrastructure and logistical capacities for storing biological products. The increase in asset value confirms the resilience of supply chains. By analyzing the calculated book value per share, one can assess the real intrinsic value of the business.

Competitor analysis for Kymera Therapeutics

GMAB - Net Assets per Single Share|Exelixis Inc. (EXEL) - Accounting Value per Share|Nuvalent, Inc. (NUVL) - Net Assets per Single Share|ideayabio.com - Accounting Value of a Share|Net Assets per Single Share Enliven Therapeutics, Inc.|Net Asset Value per Share ORIC Pharmaceuticals Inc ORIC|Net Assets per Single Share Relay Pharma (RLAY)|Nurix Corp - Equity per Share|Book Value per Share TYRA (Tyra Biosciences, Inc.)|VSTM - Accounting Value per Share|GLUE - Net Assets per Single Share|Net Asset Value per Share Cullinan Oncology|Immuneering Inc. (IMRX) - Net Assets per Single Share|CCCC (C4 Therapeutics Corp) - Net Assets per Single Share|Net Assets per Single Share Black Diamond|Net Asset Value per Share reparerx.com RPTX|Book Value per Share PMVP|karyopharm.com (KPTI) - Book Value of One Share|Propanc Biopharma - Accounting Value per Share|Cyclacel (BGMS) - Net Asset Value per Share|AADI: Accounting Value per Share|Accounting Value of a Share ALRN (Aileron Therapeutics)|BPMC (blueprintmedicines.com) - Accounting Value per Share|GLYC: Book Price of a Share|SWTX (SpringWorks) - Book Value per Share